purity
verified
every lot
KLOW
BPC-157 10mg + TB-500 10mg + GHK-Cu 50mg + KPV 10mg blend; recovery & wound research
KLOW research profile
What is KLOW?
Often referred to as the KLOW combination, this is a four-component vial containing 10 mg of BPC-157, 10 mg of TB-500, 50 mg of GHK-Cu and 10 mg of KPV as a co-lyophilized powder. It is the GLOW combination with the addition of KPV, the C-terminal tripeptide lysine-proline-valine of alpha-melanocyte-stimulating hormone, a small, uncharged, protease-resistant fragment studied as an anti-inflammatory peptide. As with the three-component vial, the copper(II) complex gives the reconstituted solution a blue colour. All four components are unapproved research compounds and the vial is supplied as a laboratory reagent.
How KLOW works: proposed mechanism
Each component has been characterised in a distinct arm of the tissue-repair and inflammation literature. BPC-157 has been reported in rodent and cell studies to upregulate VEGFR2 and engage VEGFR2-Akt-eNOS signalling and to increase growth hormone receptor expression in tendon fibroblasts, with observed effects on angiogenesis and granulation tissue in injury models. TB-500 and parent thymosin beta-4 sequester monomeric G-actin, governing cytoskeletal remodelling and directed cell migration, with additional reported integrin-linked kinase and Akt activation. GHK-Cu acts as a high-affinity copper(II) carrier supplying cuproenzymes including lysyl oxidase, and has been reported to stimulate collagen, elastin and glycosaminoglycan synthesis by fibroblasts and to shift gene expression toward a less inflammatory profile. KPV is distinctive in that it is taken up intracellularly through the oligopeptide transporter PepT1, which is upregulated on inflamed intestinal epithelium and on immune cells; once internalised it has been reported to inhibit NF-kB and MAP kinase activation and to reduce pro-inflammatory cytokine output, an action shown in murine colitis models to occur without requiring melanocortin receptor engagement. The stated combination rationale is that vascular signalling, cell migration, matrix synthesis and inflammatory signalling represent separable processes; no controlled study has evaluated this four-component combination, and no interaction, additivity or synergy has been demonstrated for it.
KLOW FDA status & development stage
No combination product containing BPC-157, TB-500, GHK-Cu and KPV has been evaluated or approved by FDA, and no such combination is the subject of an approved or investigational application. Each component is separately unapproved as a drug substance: BPC-157 and thymosin beta-4/TB-500 hold no approval and BPC-157 has been identified by FDA as presenting significant safety risks for use in compounded drug products; GHK-Cu is used as a cosmetic ingredient in topical products, a category that does not receive FDA premarket approval, and has no approved drug presentation; KPV is an alpha-MSH fragment studied only as a preclinical research peptide. This vial is a laboratory research reagent intended for in vitro and non-clinical research only.
This product is supplied as a research chemical. It is not an FDA-approved drug product regardless of the molecule's regulatory status above, and is not for human use.
Published research on KLOW
The published literature consists mainly of cell (in-vitro) and animal studies. Controlled human evidence is lacking, so findings cannot be generalized to humans.
Cited below: 3 animal studies, 1 review and 1 other (chemistry, methods or background) paper. Study types are read from each study's design; unlabelled entries are chemistry, methods or background papers.
- 1.Preclinical: animalGastroenterology · 2008
KPV entered intestinal epithelial and immune cells through the PepT1 transporter and reduced NF-kB and MAP kinase activation and pro-inflammatory cytokine secretion in cell and murine colitis models.
- 2.Preclinical: animalInflammatory Bowel Diseases · 2008
In DSS and TNBS murine colitis models KPV reduced histological inflammation scores and inflammatory mediator expression, with effects reported to be independent of classical melanocortin receptor signalling.
- 3.Preclinical: animalJournal of Molecular Medicine · 2017
BPC-157 upregulated VEGFR2 and activated the VEGFR2-Akt-eNOS pathway in endothelial cells and murine models, correlating with increased vessel formation.
- 4.International Journal of Molecular Sciences · 2018
Gene-expression data indicated that GHK-Cu shifts transcription across a broad set of genes toward a less inflammatory, more regenerative profile in human cells.
- 5.ReviewTrends in Molecular Medicine · 2005
A review describing how the actin-sequestering function of thymosin beta-4 underlies its reported effects on cell migration, angiogenesis and inflammation in animal injury models.
References are provided for scientific context only and do not constitute claims about this product.
Commonly researched together
KLOW FAQ
What is KLOW?
Often referred to as the KLOW combination, this is a four-component vial containing 10 mg of BPC-157, 10 mg of TB-500, 50 mg of GHK-Cu and 10 mg of KPV as a co-lyophilized powder. It is the GLOW combination with the addition of KPV, the C-terminal tripeptide lysine-proline-valine of alpha-melanocyte-stimulating hormone, a small, uncharged, protease-resistant fragment studied as an anti-inflammatory peptide.
What is KLOW studied for in research?
Published research on KLOW has focused on: klow combination, bpc-157, tb-500, ghk-cu and kpv, nf-kb pathway research, extracellular matrix and angiogenesis, pept1-mediated peptide uptake. It is listed under Tissue Repair & Cytoprotection in our catalog. These are areas of scientific study, not established uses — see the evidence summary and cited studies on this page.
Is KLOW FDA-approved?
No. No combination product containing BPC-157, TB-500, GHK-Cu and KPV has been evaluated or approved by FDA, and no such combination is the subject of an approved or investigational application. Each component is separately unapproved as a drug substance: BPC-157 and thymosin beta-4/TB-500 hold no approval and BPC-157 has been identified by FDA as presenting significant safety risks for use in compounded drug products; GHK-Cu is used as a cosmetic ingredient in topical products, a category that does not receive FDA premarket approval, and has no approved drug presentation; KPV is an alpha-MSH fragment studied only as a preclinical research peptide.
What does the published evidence on KLOW show?
Evidence level: Preclinical / insufficient human evidence. The published literature consists mainly of cell (in-vitro) and animal studies. Controlled human evidence is lacking, so findings cannot be generalized to humans. The 5 studies cited on this page comprise 3 animal studies, 1 review and 1 other (chemistry, methods or background) paper.
Does KLOW come with a Certificate of Analysis?
Yes. Each lot has its own Certificate of Analysis, linked on this page for the current lot of each size: (10mg+10mg+50mg+10mg) (99% HPLC purity). Past certificates are archived in the COA library; contact us with the lot number on your vial if you cannot find its certificate.
What purity is KLOW?
99% (HPLC, current lot). Purity is measured by high-performance liquid chromatography (HPLC) and reported on the lot's Certificate of Analysis.
How should KLOW be stored?
Store the sealed co-lyophilized vial at -20 degrees C, desiccated and protected from light, with particular attention to light protection because of the copper complex. Equilibrate to room temperature before opening so moisture does not condense onto the cake. Reconstitute with an appropriate sterile diluent, directing the stream down the vial wall and swirling gently; a blue solution is expected.
Can KLOW be used in humans or animals?
No. KLOW is sold strictly for in-vitro laboratory research. It is not a drug, supplement or cosmetic, is not for human or veterinary use, and we provide no dosing or administration guidance. Buyers must be 21+ and attest to research use.
Related guides & documentation
- BPC-157 vs TB-500 in Tissue Repair Research
- How to Read a Certificate of Analysis
- HPLC Purity Testing, Explained
- Storing Lyophilized Peptides in the Lab
- Reading a Compound's FDA Status
- KLOW Certificates of Analysis in the COA library
- More Tissue Repair & Cytoprotection compounds
- How we test and document every lot
- What research use only means
Researcher ratings
No ratings yet — customers are invited to rate their experience after delivery.
Ratings reflect the purchase and service experience of verified customers, not product performance claims.